Suppr超能文献

发现不对称芳基二硫化物作为新型严重急性呼吸综合征冠状病毒主要蛋白酶抑制剂:化学合成、生物学评价、分子对接和三维定量构效关系研究

Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.

作者信息

Wang Li, Bao Bo-Bo, Song Guo-Qing, Chen Cheng, Zhang Xu-Meng, Lu Wei, Wang Zefang, Cai Yan, Li Shuang, Fu Sheng, Song Fu-Hang, Yang Haitao, Wang Jian-Guo

机构信息

State-Key Laboratory and Research Institute of Elemento-Organic Chemistry, National Pesticide Engineering Research Center, College of Chemistry, Nankai University, Tianjin 300071, China.

School of Life Sciences, Tianjin University, Tianjin 300072, China; Tianjin International Joint Academy of Biotechnology and Medicine, Tianjin 300457, China.

出版信息

Eur J Med Chem. 2017 Sep 8;137:450-461. doi: 10.1016/j.ejmech.2017.05.045. Epub 2017 Jun 9.

Abstract

The worldwide outbreak of severe acute respiratory syndrome (SARS) in 2003 had caused a high rate of mortality. Main protease (M) of SARS-associated coronavirus (SARS-CoV) is an important target to discover pharmaceutical compounds for the therapy of this life-threatening disease. During the course of screening new anti-SARS agents, we have identified that a series of unsymmetrical aromatic disulfides inhibited SARS-CoV M significantly for the first time. Herein, 40 novel unsymmetrical aromatic disulfides were synthesized chemically and their biological activities were evaluated in vitro against SARS-CoV M. These novel compounds displayed excellent IC data in the range of 0.516-5.954 μM. Preliminary studies indicated that these disulfides are reversible and mpetitive inhibitors. A possible binding mode was generated via molecular docking simulation and a comparative field analysis (CoMFA) model was constructed to understand the structure-activity relationships. The present research therefore has provided some meaningful guidance to design and identify anti-SARS drugs with totally new chemical structures.

摘要

2003年严重急性呼吸综合征(SARS)在全球范围内爆发,导致了很高的死亡率。严重急性呼吸综合征冠状病毒(SARS-CoV)的主要蛋白酶(M)是发现用于治疗这种危及生命疾病的药物化合物的重要靶点。在筛选新型抗SARS药物的过程中,我们首次发现一系列不对称芳基二硫化物能显著抑制SARS-CoV M。在此,通过化学合成了40种新型不对称芳基二硫化物,并在体外评估了它们对SARS-CoV M的生物活性。这些新型化合物的IC数据优异,范围在0.516 - 5.954μM之间。初步研究表明,这些二硫化物是可逆的竞争性抑制剂。通过分子对接模拟生成了一种可能的结合模式,并构建了比较分子场分析(CoMFA)模型以了解构效关系。因此,本研究为设计和鉴定具有全新化学结构的抗SARS药物提供了一些有意义的指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edf3/7115414/a1c955b7f76f/fx1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验